Charles Yeomans has 25 years of experience in investment banking, private equity investment and M&A and has more than a decade of experience in executive management at the corporate level. Besides his role at Trigemina, he is is also a consultant to SiteOne, Inc., a Stanford-based biotechnology firm developing a subtype-selective sodium channel blocker for pain.
Mr. Yeomans was previously the president and CEO of an employee benefits brokerage and administration firm, Portal Group Holdings, which he and a small group of private equity investors acquired in 2006 and sold to Ascension Insurance in 2009. He has also held senior management positions at the large insurance brokerage Frenkel & Co., Inc., in New York City, and Ultralink, a Southern California-based employee benefits technology firm. He has been the architect of several successful fundraising efforts and mergers and acquisitions that resulted in the consolidation of some of the nation’s largest insurance brokerages.
Prior to becoming a senior manager of insurance and benefits companies, Mr. Yeomans specialized in leading mergers and acquisitions and raising capital for the insurance industry and managed his own firm Yeomans, Robinson, Inc. in that capacity. Prior to Yeomans, Robinson, he was an investment banker for Drexel Burnham Lambert.
Mr. Yeomans holds an AB degree from Kenyon College and an MBA from Stanford. He was also an intelligence officer in the U.S. Navy.
David Yeomans is the director of pain research and a tenured associate professor of anesthesia at Stanford University School of Medicine. He is the chair of the scientific advisory board of three companies and an advisor to numerous pharmaceutical and biotech companies, as well as venture capital firms and intellectual property law practices. Dr. Yeomans has authored more than 90 peer reviewed articles and 11 book chapters in the field of pain, and has been the recipient of numerous NIH grants. He has authored numerous issued patents and patent applications and co-founded two companies devoted to the management of pain.
Dr. Yeomans earned an AB degree from Dartmouth College, received his PhD in neuroscience from the University of Florida, and completed his research training as a NIH fellow at the University of Illinois.
Shashidhar Kori, M.D. joined Trigemina as chief medical officer in 2015. He brought more than 30 years of research and drug development experience in neurosciences. Before joining Trigemina, he served as chief medical officer at Autonomic Technologies, Inc. (ATI), where he was responsible for clinical research, clinical outcomes and regulatory submissions. He oversaw development and execution of all clinical research, including ATI’s clinical trials in the United States and in Europe. Prior to Joining ATI, he was vice president of clinical development and medical affairs at Allergan. Prior to Allergan, Dr. Kori was vice president of clinical development and medical affairs at MAP Pharmaceuticals, where he built the Medical Affairs department from the ground up, helped submit an NDA and multiple INDs, ran clinical operations and oversaw an active publication strategy. Prior to his time at MAP, he was senior director of clinical development at GlaxoSmithKline (GSK). In this role, Dr. Kori oversaw the design and execution of clinical studies and coordinated responses to FDA for migraine and pain products in development. In addition, Dr. Kori participated in the development of new chemical entities and managed market support for marketed products.
Prior to GSK, Dr. Kori spent 24 years in academic medicine at major U.S. medical centers and universities (Sloan Kettering Cancer Center, Case Western Reserve University, Moffitt Cancer Center and Duke University) providing him with extensive experience in clinical patient care. In this capacity, he also founded and directed four major pain programs in the U.S.; taught students and residents and was voted “Best Teacher of the Year” four times (USF), performed research where he published more than 100 publications, several grants, described two new syndromes and devised a new questionnaire; and served in administration where he was director of a residency program, vice chairman of a department, chief of service and director of several clinical programs.
He also served as president, as a member of the board of directors and committee chair of several national professional societies (AAN, SPS, ASN, SEAPC), has delivered invited lectures in more than a dozen countries, chaired several national professional seminars and symposia, was visiting professor at 10 universities, was on the editorial board or medical reviewer for seven professional journals, and has significant media exposure (appearing on several national TV programs, radio programs and quoted in national publications).
Professor Stephen D. Silberstein, MD, is Professor of Neurology and Director of the Jefferson Headache Center at Thomas Jefferson University, and a leading expert in migraine. He is a Fellow of the American College of Physicians, the American Academy of Neurology, The American Neurological Association, and the American Headache Society. He has served the American Headache Society as President, Treasurer, and Board of Directors member. He has served on the Publications, Scientific, and Education Committees of the American Headache Society and was Co-chairman of the Annual Scientific Meeting. He is current chair of the guidelines committee of the American Headache Society. Dr. Silberstein is an active member of the American Academy of Neurology and was Co-director of the national and international Headache Guideline Project, in cooperation with the Agency for Health Care Policy and Research. He was the Chairman of the International Headache Society meeting in Philadelphia in 2009. He was Chairman of the headache research group of the World Federation of Neurology.
Dr. Silberstein received his medical degree from the University of Pennsylvania. He then completed a medical internship and junior residency at the Hospital of the University of Pennsylvania. After completing a fellowship in neurology at the National Hospital for Nervous Diseases in London, Dr. Silberstein served as a Pharmacology Research Associate in the Toxicology Laboratory of Clinical Science at the National Institutes of Mental Health, and completed a neurology residency at the Hospital of the University of Pennsylvania.
Dr. Silberstein is the Senior Editor of the 8th edition of Wolff's Headache and Other Head Pain, Associate Editor of Cephalalgia and CNS Drugs, and a present or prior member of the Editorial Board of Headache; Cephalalgia; Acta Neurologica Scandinavica; Journal of Neurology, Neurosurgery & Psychiatry; and Topics in Pain Management. He is an ad hoc reviewer for many publications, including The New England Journal of Medicine; Brain, The Lancet, JAMA, Mayo Clinic Proceedings, Annals of Neurology, and Neurology. He has over 300 scientific publications.
Mike Leonard has extensive experience in mergers and acquisitions, financial management and senior level operations management and has the proven ability to raise business capital. His role with Trigemina is focused on the company’s financial management and internal operations, as well as preparing the company for its next stage of development.
Mr. Leonard is a Certified Public Accountant and has served as CFO for several insurance brokerages, including USI Holdings, Inc., the industry’s first serious venture to “buy and build” insurance service and distribution firms backed by major private equity firms. During his five years with USI, the company went from a startup operation to become one of the top ten insurance brokerage firms in the United States. This rapid growth was accomplished primarily through acquisition, for which Mr. Leonard’s role as CFO was pivotal. Since USI, Mr. Leonard has expanded his role to include senior level operations management as CFO/COO of two regional insurance services firms.
Bill St John has 25 years of experience in the biotechnology and pharmaceutical business. This experience includes serving as CEO and Chief Business Officer for several biotech firms, managing their growth to IPOs and acquisition, serving as in-coming reorganization executive for clinical phase firms, serving as Managing Director for a specialized venture capital firm and serving as a representative of a small investment banking firm.
His drug development experience includes overseeing and managing drug candidate selection, preclinical & drug development activities in multiple therapeutic areas and leading cross-functional teams that included CMC, pharmacology, DMPK/ADME, safety and clinical representatives to ensure that global regulatory filing requirements and corporate goals are accomplished according to agreed upon timelines and budgets.
Mr. St. John holds an BS degree from Seattle University and an MS in Molecular Biology from The Ohio State University.
Marc Pentopoulos, CFA has been involved in the healthcare industry in banking, investing, and strategy consulting for over 20 years. He joined Trigemina as Senior Vice President of Business Development in January of 2016. Mr. Pentopoulos was a partner at Symmetry Capital Management, a life science fund investing in publically traded equities, as well as the owner of Vista Point Capital, a consulting/advisory firm in the healthcare industry. Previously, he founded the EGM Medical Technology Fund at EGM Capital in San Francisco and successfully ran that fund for a number of years, which was consistently a top performing healthcare fund, as reported by Barron’s. Mr. Pentopoulos was also the founder of Genaissance Capital, and has served a research analyst at Perceptive Life Sciences, Genesis Merchant Group and as an analyst in the investment-banking group at Cowen & Co.
He has an MBA from the Wharton School and graduated with honors from UC Berkeley with Bachelor of Arts degrees in Molecular and Cell Biology and Economics. He also is a CFA holder and has his series 79 and 63 licenses.
Dr. Ramachandran “TR” Thirucote, is an industry veteran with over 25 years in pharmaceuticals. As an industrial pharmacist, he has extensive hands-on and management experience in the formulation design and development of various dosage forms for the pharmaceutical and biopharmaceutical industries. He has successfully developed and helped launch various products including parenteral dosage forms, tablets, capsules, ointments, creams, as well as novel controlled delivery systems. As the vice president of pharmaceutical sciences at RoxRo Pharma, LLC, TR was responsible for the entire design, development and commercial launch of SPRIX®, a unique and complex metered nasal spray drug-device combination for non-opioid, post-operative pain management, approved for use by the FDA in 2010.
Dr. Thirucote is a reputed scientist with several publications, primary inventor named on several patents and an invited speaker at national and international symposia. He is an active participant and industry consultant to the National Institute of Health (NIH) and the Special Emphasis Review Panel for the National Institute of Allergy and Infectious Diseases (NIAID). He is currently the chief executive officer at TesoRx Pharma, LLC, a mid – to late-stage virtual pharmaceutical company.
Jean Chang has more than 20 years of experience in the pharmaceutical industry with focused knowledge and expertise in clinical program management, operations, trial management, and vendor management. She joined Trigemina in March 2016 as Director of Clinical Operations and has been responsible for all the operational aspects of clinical trials.
Mrs. Chang's clinical experience spans from IND submission and early development through NDA submission in the neurosciences, respiratory, cardiovascular, and oncology fields. Prior to joining Trigemina, Mrs. Chang held several senior positions in clinical operations at Sorbent Therapeutics, MAP Pharmaceuticals, and Maxygen Inc. She has extensive experience in the management of migraine headache clinical trials and had direct contribution to a pivotal study and the successful filing of an NDA for a migraine drug during her employment at MAP Pharmaceuticals.
Mrs. Chang holds a Master of Science in Life Sciences from Wayne State University and a Bachelor of Science in Medical Technology from China Medical College in Taiwan.
Kayla Danna has a decade of experience in financial modeling and analysis, fiscal budgeting, management and forecasting, financial reporting, oversight of internal controls, bank reporting, and debt covenant compliance. Most recently, she served as a senior financial analyst of a consulting firm specializing in M&A transactions.
Ms. Danna’s experience with government compliance codes is particularly relevant in the biotech industry due to the strong interaction between commercial enterprise, regulatory agencies and organizations providing grant funding to biotech firms.
Ms. Danna completed a bachelor of arts degree from Sacramento State and a master’s of public administration (MPA) degree with an emphasis in policy from Cal State University East Bay. She has also earned an MBA in finance from St. Mary’s College.